ARA-290 (Cibinetide)

Description

ARA 290 (or Cibinetide) is an investigational non-erythropoietic peptide designed to treat neuropathic pain and inflammation by targeting the innate repair receptor (IRR). Clinical studies have investigated its use in sarcoidosis, type 2 diabetes, and diabetic macular edema. It is often administered as a 4 mg daily subcutaneous injection.

Key Aspects of the ARA 290 Protocol:

Mechanism: Interacts selectively with the Innate Repair Receptor (IRR) to reduce inflammation, promote tissue protection, and repair nerve damage without inducing red blood cell production.

Target Conditions:
Sarcoidosis-associated small fiber neuropathy: Evaluated for reducing neuropathic symptoms and improving corneal nerve fiber density.
Type 2 Diabetes & Painful Neuropathy: Studied for improving HbA1c, lipid profiles, and reducing neuropathic pain (e.g., using Pain detect questionnaires).
Duration: Clinical studies have utilized a 28-day treatment phase, followed by observation periods of one to two months.
Safety: Studies have indicated no significant safety issues, and the drug is generally well-tolerated, with monitoring for potential anti-drug antibodies.The drug has been granted Orphan Drug designation by the FDA for the treatment of sarcoidosis. It is derived from the structure of erythropoietin but modified to eliminate the risk of stimulating blood cell production.